BackHorizon Therapeutics Plc Overview

Horizon Therapeutics Plc Other Liabilities

Horizon Therapeutics Plc's other liabilities is $0.

Get informed when a big investor buys or sells

+ Follow
Other Liabilities
$0.00
100.00% YoYΔ $-199.65M vs prior year quarter

Peer average

Loading

Horizon Therapeutics Plc Other Liabilities History

Loading

Horizon Therapeutics Plc vs. peers: Other Liabilities Comparison

Loading

Horizon Therapeutics Plc Other Liabilities Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Horizon Therapeutics Plc (HZNP) FAQ

Horizon Therapeutics Plc (HZNP) currently reports a other liabilities of $0 as of June 2023. That compares with $200M in the prior-year period — down 100.0% year over year. Use the charts on this page to explore Horizon Therapeutics Plc's other liabilities history and peer comparisons.

Horizon Therapeutics Plc's other liabilities decreased from $200M to $0 — a 100.0% year-over-year decrease (period ending June 2023). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Horizon Therapeutics Plc reported $0 in other liabilities as of June 2023. That compares with $200M in the prior-year period — down 100.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current other liabilities of $0, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Horizon Therapeutics Plc, and consider following HZNP for alerts when major investors trade the stock.

Horizon Therapeutics Plc is classified in the Healthcare sector. On other liabilities, it currently shows $0. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing HZNP with unrelated industries.